Medicinal Products of Darnitsa Meet the New European Guidelines for the Management of Arterial Hypertension16 October 2018
New Joint Guidelines of the European Society of Hypertension and the European Society of Cardiology for the prevention, diagnosis and treatment of arterial hypertension were presented during the annual European meeting on arterial hypertension and cardiovascular prophylaxis held in Barcelona (Spain) in June.
Larysa Mishchenko, Doctor of Medical Sciences, who participated in said forum, told about the latest guidelines for the prevention, diagnosis and treatment of arterial hypertension.
“Arterial hypertension (AH) remains the hottest point not only in cardiology, but also in medicine in general. Unfortunately, according to the WHO, today it is high arterial blood pressure (AP) that is the leader among other risk factors that lead to death in the world,” Larysa Anatoliivna observes.
According to her, there has not been much news in the field of treatment of arterial hypertension lately: “Guidelines for the treatment of cardiovascular diseases are updated on average every 5 years. And this year, the time has come for the guidelines for the diagnosis and treatment of arterial hypertension, due to which we have received answers to one of the most pressing questions - how we will treat patients with arterial hypertension in the next 5 years. This news will be of interest not only to doctors, but also to pharmacists, because it depends on pharmaceutical manufacturers, inter alia, how we will treat patients with arterial hypertension”.
European experts, unlike American ones, have left the classification of arterial hypertension according to the level of blood pressure and the diagnostic limit of hypertension unchanged. It should be taken into account, because in Europe and in Ukraine this limit is AP140 and / or 90 mm Hg. While US recommendations in 2017 introduced new criteria for AH-AP 130 and / or 80 mm Hg.
Speaking of the news in the field of AH diagnostics, the guidelines emphasize the importance of widespread introduction of outpatient methods of blood pressure measurement into the clinical practice. Unlike office measurements, 24-hour blood pressure monitoring and home blood pressure monitoring can improve diagnosis and individualize treatment approaches.
Larysa Mishchenko emphasized the importance of the 28th European Congress on Arterial Hypertension and Cardiovascular Prophylaxis for both scientists and doctors and noted the role of the interaction between healthcare professionals and pharmaceutical companies. It is due to such cooperation that the results of the study of treatment of patients with resistant arterial hypertension with “Tira Trio®” medicinal product manufactured by the PrJSC “Pharmaceutical Firm “Darnitsa” were presented within the framework of the Congress.
Larysa Mishchenko, Doctor of Medical Sciences:
“Prior to discussing new approaches in treatment of patients with hypertension, it is necessary to determine the target level of blood pressure. European experts have chosen a fairly balanced approach in this matter. The primary goal of treatment is to reduce the blood pressure to less than 140/90 mm Hg. In case of achieving this level of blood pressure under the condition of its good tolerability, we must strive for control of blood pressure at 130/80 mm Hg and below. However, for certain categories of patients it is not recommended to reduce the blood pressure to less than 130/80 mm Hg, especially at the age of 60 years, where there are ischemic heart disease and chronic kidney disease. The basis of treatment for a patient with hypertension is the modification of the lifestyle, which is accompanied by drug therapy. The new strategy provides for combined antihypertensive therapy from the start of treatment for the majority of patients with hypertension. And the main condition for the wider use of combination therapy is to use it in the form of a fixed combination, that is, in one tablet. If two-component therapy in optimal doses is inefficient, the next step should be a triple fixed combination, again in one tablet.
Such approach contributes to a real increase in the efficiency of antihypertensive therapy, as also evidenced by our experience. In the Department of Hypertension, a study was undertaken to evaluate the effectiveness of Tiara Trio® medicinal product in patients with a previous diagnosis of resistant hypertension. Such a diagnosis involves the ineffectiveness of therapy with three antihypertensive drugs, one of which is a diuretic. When included in the study patients received an average of about 3 pills a day. After an examination, patients were transferred to standardized treatment with a triple fixed combination of amlodipine / HCTZ / valsartan (“Tiara Trio®”) at the maximum dose. After 3 months of such treatment, about 40% reached the target level of blood pressure, that is, they ceased to be resistant to treatment. Such an impressive result was achieved through the use of a rational combination in an adequate dose in the form of a single pill.
According to Larysa Anatoliivna, Darnitsa looks ahead through the prism of active cooperation with scientists in conducting research on the implementation of their own developments. “The key to sustainable development of the pharmaceutical industry and medical science is the cooperation and development of joint projects, which will make it possible to achieve success not only in Ukraine but also abroad”.